Structure Encountered
Alaw Therapeutics
Precision oncology company developing brain-penetrant CDK inhibitors for solid tumors
Alaw dosed the first patient in its brain-penetrant CDK2 trial and nominated a CDK4 candidate.
SIGNAL·Phase 1a/b first patient + AL-433 nomination·2 brain-penetrant CDKs·SCORE 72·02 JUN 2026 · 11:54 UTC
● CAPTURE — IMAGE INCOMINGFRAME 01 / 01
STRUCT. / ALAW THERAPEUTICS
/ San Diego, CA, United States
CAPT. / 02.06.26 11:54:29Z
SIGNAL / 72 / 100
Image relayed by The Biotech Voyager during pass over structure Alaw Therapeutics. Resolution as transmitted.
001Vital Statistics
DATA LOCKED
Designation
Alaw Therapeutics
Coordinates
San Diego, CA, United States
Stage
Phase1
Type
Therapeutics
Modalities
small molecule
Therapeutic area
Oncology · Neurology
002Signature Detected
EVENT DETECTED
Event type
Phase 1a/b first patient + AL-433 nomination
Magnitude
2 brain-penetrant CDKs
Lead
Alaw Therapeutics
Participating
Eilean Therapeutics (parent)
003Architecture
PLATFORM PROFILE
Target class
CDK2 (AL-605) and CDK4 (AL-433), cell-cycle kinases driving tumor proliferation. CDK2 is the main escape route after CDK4/6 inhibitor resistance; both are designed to cross the blood-brain barrier.
Differentiator
Approved CDK4/6 drugs barely cross into the brain, leaving CNS tumors and brain metastases untreated. Alaw built both inhibitors to penetrate the blood-brain barrier, and aimed CDK2 at the CCNE1-amplified tumors that escape CDK4/6 therapy.
Lead asset
AL-605, brain-penetrant CDK2 inhibitor, Phase 1a/b
Pipeline depth
2 disclosed: AL-605 (Ph1a/b), AL-433 (CDK4, FIH Q4 2026); RIPTAC degraders behind
004Voyager Assessment
MACHINE-GENERATED
Two announcements, one thesis. Alaw is betting on the brain. The CDK4/6 drugs that reshaped HR-positive breast cancer, Ibrance, Verzenio, Kisqali, mostly stop at the blood-brain barrier, so brain metastases go untreated and CDK2 amplification becomes the escape hatch when they stop working. AL-605 goes after that escape hatch, CDK2, and it is built to reach the brain. First patient is dosed in CCNE1-amplified tumors. AL-433, a brain-penetrant CDK4, is right behind it for a Q4 first-in-human. Watch the interim AL-605 readout in the second half of 2026.
005Adjacent Structures
FRONTIER MAP
Avenzo Therapeutics· CDK4 + CDK2, breastBlueprint Medicines· BLU-222, CDK2 inhibitorPfizer· Ibrance, CDK4-selectiveEli Lilly· abemaciclib incumbentNovartis· ribociclib incumbent
— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.